

Table 5. Summary of all ertapenem clinical studies

Type of infection	Number of patients	Clinical response to ertapenem	Clinical response to comparator
Complicated intra-abdominal infections	455	86.8%	83.1% piperacillin/tazobactam
	69	89%	94% ceftriaxone/metronidazole
	73	90%	86% ceftriaxone/metronidazole
Complicated skin and skin structure infections	127	80.3%	77.0% piperacillin/tazobactam
	359	82.4%	84.4% piperacillin/tazobactam
Community-acquired pneumonia	275	92.2%	93.6% ceftriaxone
	383	92.3%	91.0% ceftriaxone
	658	91.9%	92.0% ceftriaxone
	28	93.0%	85.0% ceftriaxone
Complicated UTI	330	91.8%	93.0% ceftriaxone
	150	85.6%	84.9% ceftriaxone
	480	89.4%	91.1% ceftriaxone
Acute pelvic infections	316	93.9%	91.5% piperacillin/tazobactam